Get startedLog in
    Picture of ORYZON Genomics SA logo

    ORY — ORYZON Genomics SA News Story

    0.000.00%
    es flag iconLast trade - 00:00
    HealthcareSpeculativeSmall CapSucker Stock
    All News

    Brief: Oryzon Announces First Patient Dosed In Phase I Study Of Iadademstat In Myelodysplastic Syndrome

    Picture of ORYZON Genomics SA logoORYZON Genomics SA
    23/01/2025 13:13
    Jan 23 (Reuters) - Oryzon Genomics SA  ORY.MC :
    * ORYZON ANNOUNCES FIRST PATIENT DOSED IN AN
INVESTIGATOR-INITIATED PHASE I STUDY OF IADADEMSTAT IN
MYELODYSPLASTIC SYNDROME

Source text:  ID:nGNX9HKsk3 
Further company coverage:  ORY.MC

    Recent news on ORYZON Genomics SA

    See all news